Northern Trust
TRVI icon

Northern Trust’s Trevi Therapeutics TRVI Stock Holding History

Northern Trust’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8M Buy
1,006,038
+199,379
+25% +$2.9M ﹤0.01% 1841
2026
Q1 		$9.62M Buy
806,659
+44,693
+6% +$500K ﹤0.01% 2104
2025
Q4 		$9.54M Buy
761,966
+25,036
+3% +$289K ﹤0.01% 2109
2025
Q3 		$6.74M Buy
736,930
+160,459
+28% +$1.2M ﹤0.01% 2325
2025
Q2 		$3.15M Buy
576,471
+10,274
+2% +$63.9K ﹤0.01% 2742
2025
Q1 		$3.56M Buy
566,197
+83,382
+17% +$398K ﹤0.01% 2604
2024
Q4 		$1.99M Buy
482,815
+49,173
+11% +$157K ﹤0.01% 3026
2024
Q3 		$1.45M Buy
433,642
+112,540
+35% +$335K ﹤0.01% 3179
2024
Q2 		$957K Sell
321,102
-6,590
-2% -$18.3K ﹤0.01% 3266
2024
Q1 		$1.13M Buy
327,692
+13,514
+4% +$30.2K ﹤0.01% 3261
2023
Q4 		$421K Sell
314,178
-1,378
-0.4% -$2.09K ﹤0.01% 3599
2023
Q3 		$688K Sell
315,556
-6,001
-2% -$13.6K ﹤0.01% 3421
2023
Q2 		$769K Buy
321,557
+257,374
+401% +$649K ﹤0.01% 3439
2023
Q1 		$119K Buy
64,183
+10,068
+19% +$22.8K ﹤0.01% 4041
2022
Q4 		$104K Buy
54,115
+14,188
+36% +$28K ﹤0.01% 4077
2022
Q3 		$61K Sell
39,927
-6,371
-14% -$20.9K ﹤0.01% 4273
2022
Q2 		$130K Buy
46,298
+34,884
+306% +$85.7K ﹤0.01% 4072
2022
Q1 		$25K Hold
11,414
– – ﹤0.01% 4649
2021
Q4 		$9K Hold
11,414
– – ﹤0.01% 4744
2021
Q3 		$16K Hold
11,414
– – ﹤0.01% 4618
2021
Q2 		$26K Hold
11,414
– – ﹤0.01% 4528
2021
Q1 		$31K Hold
11,414
– – ﹤0.01% 4418
2020
Q4 		$28K Hold
11,414
– – ﹤0.01% 4296
2020
Q3 		$46K Sell
11,414
-4,588
-29% -$21.6K ﹤0.01% 4115
2020
Q2 		$105K Sell
16,002
-478
-3% -$1.68K ﹤0.01% 3907
2020
Q1 		$54K Hold
16,480
– – ﹤0.01% 3943
2019
Q4 		$62K Hold
16,480
– – ﹤0.01% 4019
2019
Q3 		$74K Hold
16,480
– – ﹤0.01% 3989
2019
Q2 		$124K Buy
+16,480
New +$142K ﹤0.01% 3928

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Northern Trust's TRVI Position: Q2 2026 in Review

Northern Trust increased its Trevi Therapeutics (TRVI) stake by 25% in Q2 2026, buying an estimated $2.9M and bringing the position to 1,006,038 shares worth $18.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

Northern Trust first reported a position in TRVI in Q2 2019 and has held it in 29 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Northern Trust held 1,006,038 shares of Trevi Therapeutics worth $18.8M as of Q2 2026.
  • Northern Trust bought 199,379 Trevi Therapeutics shares in Q2 2026, an estimated $2.9M.
  • Trevi Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1841 holding.
  • Northern Trust first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.